514 related articles for article (PubMed ID: 34556813)
1. Phenotypic plasticity of myeloid cells in glioblastoma development, progression, and therapeutics.
Ye Z; Ai X; Zhao L; Fei F; Wang P; Zhou S
Oncogene; 2021 Oct; 40(42):6059-6070. PubMed ID: 34556813
[TBL] [Abstract][Full Text] [Related]
2. Changes in the tumor microenvironment and outcome for TME-targeting therapy in glioblastoma: A pilot study.
Ali S; Borin TF; Piranlioglu R; Ara R; Lebedyeva I; Angara K; Achyut BR; Arbab AS; Rashid MH
PLoS One; 2021; 16(2):e0246646. PubMed ID: 33544755
[TBL] [Abstract][Full Text] [Related]
3. Combination anti-CXCR4 and anti-PD-1 immunotherapy provides survival benefit in glioblastoma through immune cell modulation of tumor microenvironment.
Wu A; Maxwell R; Xia Y; Cardarelli P; Oyasu M; Belcaid Z; Kim E; Hung A; Luksik AS; Garzon-Muvdi T; Jackson CM; Mathios D; Theodros D; Cogswell J; Brem H; Pardoll DM; Lim M
J Neurooncol; 2019 Jun; 143(2):241-249. PubMed ID: 31025274
[TBL] [Abstract][Full Text] [Related]
4. Preclinical ImmunoPET Imaging of Glioblastoma-Infiltrating Myeloid Cells Using Zirconium-89 Labeled Anti-CD11b Antibody.
Nigam S; McCarl L; Kumar R; Edinger RS; Kurland BF; Anderson CJ; Panigrahy A; Kohanbash G; Edwards WB
Mol Imaging Biol; 2020 Jun; 22(3):685-694. PubMed ID: 31529407
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of caveolin-1 restores myeloid cell function in human glioblastoma.
Shimato S; Anderson LM; Asslaber M; Bruce JN; Canoll P; Anderson DE; Anderson RC
PLoS One; 2013; 8(10):e77397. PubMed ID: 24130882
[TBL] [Abstract][Full Text] [Related]
6. The N
Zhao R; Li B; Zhang S; He Z; Pan Z; Guo Q; Qiu W; Qi Y; Zhao S; Wang S; Chen Z; Zhang P; Guo X; Xue H; Li G
Front Immunol; 2021; 12():653711. PubMed ID: 34354698
[TBL] [Abstract][Full Text] [Related]
7. Glioblastoma-Derived IL6 Induces Immunosuppressive Peripheral Myeloid Cell PD-L1 and Promotes Tumor Growth.
Lamano JB; Lamano JB; Li YD; DiDomenico JD; Choy W; Veliceasa D; Oyon DE; Fakurnejad S; Ampie L; Kesavabhotla K; Kaur R; Kaur G; Biyashev D; Unruh DJ; Horbinski CM; James CD; Parsa AT; Bloch O
Clin Cancer Res; 2019 Jun; 25(12):3643-3657. PubMed ID: 30824583
[TBL] [Abstract][Full Text] [Related]
8. Myeloid Cells in Glioblastoma Microenvironment.
De Leo A; Ugolini A; Veglia F
Cells; 2020 Dec; 10(1):. PubMed ID: 33374253
[TBL] [Abstract][Full Text] [Related]
9. Aging- and Tumor-Mediated Increase in CD8
Huff WX; Bam M; Shireman JM; Kwon JH; Song L; Newman S; Cohen-Gadol AA; Shapiro S; Jones T; Fulton K; Liu S; Tanaka H; Liu Y; Wan J; Dey M
Immunohorizons; 2021 Jun; 5(6):395-409. PubMed ID: 34103370
[TBL] [Abstract][Full Text] [Related]
10. The immune cell landscape of glioblastoma patients highlights a myeloid-enriched and immune suppressed microenvironment compared to metastatic brain tumors.
Musca B; Russo MG; Tushe A; Magri S; Battaggia G; Pinton L; Bonaudo C; Della Puppa A; Mandruzzato S
Front Immunol; 2023; 14():1236824. PubMed ID: 37936683
[TBL] [Abstract][Full Text] [Related]
11. Immature myeloid cells in the tumor microenvironment: Implications for immunotherapy.
Kamran N; Chandran M; Lowenstein PR; Castro MG
Clin Immunol; 2018 Apr; 189():34-42. PubMed ID: 27777083
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic targeting of tumor-associated myeloid cells synergizes with radiation therapy for glioblastoma.
Zhang P; Miska J; Lee-Chang C; Rashidi A; Panek WK; An S; Zannikou M; Lopez-Rosas A; Han Y; Xiao T; Pituch KC; Kanojia D; Balyasnikova IV; Lesniak MS
Proc Natl Acad Sci U S A; 2019 Nov; 116(47):23714-23723. PubMed ID: 31712430
[TBL] [Abstract][Full Text] [Related]
13. Role of AHR in the control of GBM-associated myeloid cells.
Gabriely G; Quintana FJ
Semin Cancer Biol; 2020 Aug; 64():13-18. PubMed ID: 31128300
[TBL] [Abstract][Full Text] [Related]
14. Mechanism and therapeutic potential of tumor-immune symbiosis in glioblastoma.
Pang L; Khan F; Heimberger AB; Chen P
Trends Cancer; 2022 Oct; 8(10):839-854. PubMed ID: 35624002
[TBL] [Abstract][Full Text] [Related]
15. Glioblastoma Immunotherapy Targeting the Innate Immune Checkpoint CD47-SIRPĪ± Axis.
Hu J; Xiao Q; Dong M; Guo D; Wu X; Wang B
Front Immunol; 2020; 11():593219. PubMed ID: 33329583
[TBL] [Abstract][Full Text] [Related]
16. Neoadjuvant PD-1 blockade induces T cell and cDC1 activation but fails to overcome the immunosuppressive tumor associated macrophages in recurrent glioblastoma.
Lee AH; Sun L; Mochizuki AY; Reynoso JG; Orpilla J; Chow F; Kienzler JC; Everson RG; Nathanson DA; Bensinger SJ; Liau LM; Cloughesy T; Hugo W; Prins RM
Nat Commun; 2021 Nov; 12(1):6938. PubMed ID: 34836966
[TBL] [Abstract][Full Text] [Related]
17. Understanding the immunosuppressive microenvironment of glioma: mechanistic insights and clinical perspectives.
Lin H; Liu C; Hu A; Zhang D; Yang H; Mao Y
J Hematol Oncol; 2024 May; 17(1):31. PubMed ID: 38720342
[TBL] [Abstract][Full Text] [Related]
18. Anti-PD-1 Induces M1 Polarization in the Glioma Microenvironment and Exerts Therapeutic Efficacy in the Absence of CD8 Cytotoxic T Cells.
Rao G; Latha K; Ott M; Sabbagh A; Marisetty A; Ling X; Zamler D; Doucette TA; Yang Y; Kong LY; Wei J; Fuller GN; Benavides F; Sonabend AM; Long J; Li S; Curran M; Heimberger AB
Clin Cancer Res; 2020 Sep; 26(17):4699-4712. PubMed ID: 32554515
[TBL] [Abstract][Full Text] [Related]
19. Pharmacological targeting of the tumor-immune symbiosis in glioblastoma.
Pang L; Khan F; Dunterman M; Chen P
Trends Pharmacol Sci; 2022 Aug; 43(8):686-700. PubMed ID: 35534356
[TBL] [Abstract][Full Text] [Related]
20. The Eclectic Nature of Glioma-Infiltrating Macrophages and Microglia.
Arrieta VA; Najem H; Petrosyan E; Lee-Chang C; Chen P; Sonabend AM; Heimberger AB
Int J Mol Sci; 2021 Dec; 22(24):. PubMed ID: 34948178
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
